From Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto:

Ed Hurwitz
Ed Hurwitz—

Headshot of Ed Hurwitz, chairman of BioIntervene and managing director at MPM Capital. Photo used courtesy of BioIntervene.

Xconomy on Demand

We offer a number of ways to subscribe for free!

Subscribe Now

© 2007-2021, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.